基于RNA干扰的慢性乙型肝炎病毒感染患者和黑猩猩治疗揭示整合的乙型肝炎病毒DNA是HBsAg的来源
该研究在RNA干扰疗法ARC-520的临床试验中发现,HBsAg在HBeAg阳性初治患者中大幅下降,但在HBeAg阴性或长期接受核苷(酸)类药物治疗的患者中降幅明显较小。在黑猩猩中的研究证明,HBsAg不仅来自cccDNA,也来自整合入宿主基因组的HBV DNA转录本,且后者是HBeAg阴性黑猩猩中的主要来源,许多整合片段缺乏ARC-520的靶位点。
要点
- ARC-520治疗在HBeAg阳性初治患者中大幅降低HBsAg,在HBeAg阴性或长期NUC治疗患者中降幅明显较小。
- 黑猩猩研究显示HBsAg可来自整合的HBV DNA转录本,且为HBeAg阴性黑猩猩中的主要来源。
- 许多整合片段缺乏ARC-520的靶位点,可解释HBeAg阴性者应答减弱。
核心结论
- 研究揭示整合的HBV DNA是HBsAg的一个来源,可能代表HBV在宿主免疫监视下维持慢性感染的策略。
- 这些结果可能改变慢性HBV新疗法的试验设计和终点预期。
研究设计与样本
- 一项基于RNA干扰的疗法ARC-520的临床试验,以及在慢性感染HBV的黑猩猩中进行的分子机制研究。
主要发现
- 在ARC-520临床试验中,HBeAg阳性初治患者的HBsAg强烈降低,而HBeAg阴性或长期接受NUC治疗的患者降低显著较少。
- 在黑猩猩中,多条证据表明HBsAg不仅来自游离的cccDNA微染色体,也来自整合入宿主基因组的HBV DNA转录本。
- 在HBeAg阴性黑猩猩中,整合的HBV DNA是HBsAg的主要来源;许多整合片段缺乏ARC-520中小干扰RNA的靶位点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic hepatitis B virus (HBV) infection is a major health concern worldwide, frequently leading to liver cirrhosis, liver failure, and hepatocellular carcinoma. Evidence suggests that high viral antigen load may play a role in chronicity. Production of viral proteins is thought to depend on transcription of viral covalently closed circular DNA (cccDNA). In a human clinical trial with an RNA interference (RNAi)-based therapeutic targeting HBV transcripts, ARC-520, HBV S antigen (HBsAg) was strongly reduced in treatment-naïve patients positive for HBV e antigen (HBeAg) but was reduced significantly less in patients who were HBeAg-negative or had received long-term therapy with nucleos(t)ide viral replication inhibitors (NUCs). HBeAg positivity is associated with greater disease risk that may be moderately reduced upon HBeAg loss. The molecular basis for this unexpected differential response was investigated in chimpanzees chronically infected with HBV. Several lines of evidence demonstrated that HBsAg was expressed not only from the episomal cccDNA minichromosome but also from transcripts arising from HBV DNA integrated into the host genome, which was the dominant source in HBeAg-negative chimpanzees. Many of the integrants detected in chimpanzees lacked target sites for the small interfering RNAs in ARC-520, explaining the reduced response in HBeAg-negative chimpanzees and, by extension, in HBeAg-negative patients. Our results uncover a heretofore underrecognized source of HBsAg that may represent a strategy adopted by HBV to maintain chronicity in the presence of host immunosurveillance. These results could alter trial design and endpoint expectations of new therapies for chronic HBV.
引用
- Wooddell CI, Yuen MF, Chan HL, et al. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Sci Transl Med. 2017. PMID: 28954926. doi:10.1126/scitranslmed.aan0241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。